UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000052689
Receipt number R000060119
Scientific Title Association between strains on intensive care units and clinical outcomes during COVID-19 pandemics in Japan: a multi-center retrospective cohort study
Date of disclosure of the study information 2023/12/01
Last modified on 2023/11/02 21:22:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association between strains on intensive care units and clinical outcomes during COVID-19 pandemics in Japan: a multi-center retrospective cohort study

Acronym

Association between strains on intensive care units and clinical outcomes during COVID-19 pandemics in Japan: a multi-center retrospective cohort study

Scientific Title

Association between strains on intensive care units and clinical outcomes during COVID-19 pandemics in Japan: a multi-center retrospective cohort study

Scientific Title:Acronym

Association between strains on intensive care units and clinical outcomes during COVID-19 pandemics in Japan: a multi-center retrospective cohort study

Region

Japan


Condition

Condition

Non-COVID-19 adult patients who admitted to intensive care units

Classification by specialty

Intensive care medicine Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to investigate the clinical managememt of non-COVID-19 critically ill patient care during the COVID-19 pandemic and to evaluate in-hospital mortality with that before the COVID-19 pandemic, according to the strain on medical resources.

Basic objectives2

Others

Basic objectives -Others

Medical strain is assessed for each participating hospital based on clinical data from the COVID-19 pandemic at each facility. In addition, for each pandemic wave, the impact of the presence or absence of medical strain on medical care will be examined.

Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

standardized mortality ratio

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Non-COVID-19 patients who admitted to ICU

Key exclusion criteria

Re-admitted patient and confirmed or suspected COVID-19

Target sample size

631


Research contact person

Name of lead principal investigator

1st name Masaaki
Middle name
Last name Sakuraya

Organization

JA Hiroshima General Hospital

Division name

Department of Emergency and Intensive Care Medicine

Zip code

738-8503

Address

1-3-3 Jigozen, Hatsukaichi, Hiroshima

TEL

0829-36-3111

Email

masaaki.sakuraya@gmail.com


Public contact

Name of contact person

1st name Masaaki
Middle name
Last name Sakuraya

Organization

JA Hiroshima General Hospital

Division name

Department of Emergency and Intensive Care Medicine

Zip code

738-8503

Address

1-3-3 Jigozen, Hatsukaichi, Hiroshima

TEL

0829-36-3111

Homepage URL


Email

masaaki.sakuraya@gmail.com


Sponsor or person

Institute

JA Hiroshima General Hospital

Institute

Department

Personal name

Masaaki Sakuraya


Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Graduate School of Biomedical and Health Sciences, Hiroshima University

Address

1-2-3 Kasumi, Minami-ku, Hiroshima

Tel

082-257-5947

Email

iryo-sinsa@office.hiroshima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 07 Month 26 Day

Date of IRB

2023 Year 10 Month 25 Day

Anticipated trial start date

2023 Year 11 Month 01 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We divide the facilities into two groups based on the number of severely ill COVID-19 patients and the results of the medical shortage questionnaire, and evaluate the change in standardized mortality ratios before and after the COVID-19 pandemic.


Management information

Registered date

2023 Year 11 Month 02 Day

Last modified on

2023 Year 11 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060119


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name